These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 32233239

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. [ARV-7: A biomarker for the treatment of metastatic castration-resistant prostate cancer].
    Chen ZY, Dong Q, Liu LR, Wei Q.
    Zhonghua Nan Ke Xue; 2019 Feb; 25(2):172-176. PubMed ID: 32216207
    [Abstract] [Full Text] [Related]

  • 3. [Splice variant AR-V7 : Is it time for its routine use as a predictive marker in prostate cancer?].
    Tsaur I, Becker C, Thelen P, Roos FC.
    Urologe A; 2017 Sep; 56(9):1164-1167. PubMed ID: 28702748
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. AR-V7 Transcripts in Whole Blood RNA of Patients with Metastatic Castration Resistant Prostate Cancer Correlate with Response to Abiraterone Acetate.
    Todenhöfer T, Azad A, Stewart C, Gao J, Eigl BJ, Gleave ME, Joshua AM, Black PC, Chi KN.
    J Urol; 2017 Jan; 197(1):135-142. PubMed ID: 27436429
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Serial blood-based analysis of AR-V7 in men with advanced prostate cancer.
    Nakazawa M, Lu C, Chen Y, Paller CJ, Carducci MA, Eisenberger MA, Luo J, Antonarakis ES.
    Ann Oncol; 2015 Sep; 26(9):1859-1865. PubMed ID: 26117829
    [Abstract] [Full Text] [Related]

  • 8. [AR-V7 Androgen Receptor Variant as a Predictor of Response to Androgen-receptor Targeting Agents Used to Treat Castration-refractory Metastatic Prostate Cancer].
    Büchler T, Bobek V, Kološtová K.
    Klin Onkol; 2017 Sep; 31(1):9-14. PubMed ID: 29488772
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Branched Chain RNA In Situ Hybridization for Androgen Receptor Splice Variant AR-V7 as a Prognostic Biomarker for Metastatic Castration-Sensitive Prostate Cancer.
    Saylor PJ, Lee RJ, Arora KS, Deshpande V, Hu R, Olivier K, Meneely E, Rivera MN, Ting DT, Wu CL, Miyamoto DT.
    Clin Cancer Res; 2017 Jan 15; 23(2):363-369. PubMed ID: 27440270
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Development of AR-V7 as a putative treatment selection marker for metastatic castration-resistant prostate cancer.
    Luo J.
    Asian J Androl; 2016 Jan 15; 18(4):580-5. PubMed ID: 27174161
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients.
    Del Re M, Biasco E, Crucitta S, Derosa L, Rofi E, Orlandini C, Miccoli M, Galli L, Falcone A, Jenster GW, van Schaik RH, Danesi R.
    Eur Urol; 2017 Apr 15; 71(4):680-687. PubMed ID: 27733296
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Clinical Relevance of Androgen Receptor Splice Variants in Castration-Resistant Prostate Cancer.
    Maughan BL, Antonarakis ES.
    Curr Treat Options Oncol; 2015 Dec 15; 16(12):57. PubMed ID: 26537882
    [Abstract] [Full Text] [Related]

  • 17. Analytical Validation of Androgen Receptor Splice Variant 7 Detection in a Clinical Laboratory Improvement Amendments (CLIA) Laboratory Setting.
    Lokhandwala PM, Riel SL, Haley L, Lu C, Chen Y, Silberstein J, Zhu Y, Zheng G, Lin MT, Gocke CD, Partin AW, Antonarakis ES, Luo J, Eshleman JR.
    J Mol Diagn; 2017 Jan 15; 19(1):115-125. PubMed ID: 27916435
    [Abstract] [Full Text] [Related]

  • 18. Growth Inhibition by Testosterone in an Androgen Receptor Splice Variant-Driven Prostate Cancer Model.
    Nakata D, Nakayama K, Masaki T, Tanaka A, Kusaka M, Watanabe T.
    Prostate; 2016 Dec 15; 76(16):1536-1545. PubMed ID: 27473672
    [Abstract] [Full Text] [Related]

  • 19. Assessment of Androgen Receptor Splice Variant-7 as a Biomarker of Clinical Response in Castration-Sensitive Prostate Cancer.
    Sowalsky AG, Figueiredo I, Lis RT, Coleman I, Gurel B, Bogdan D, Yuan W, Russo JW, Bright JR, Whitlock NC, Trostel SY, Ku AT, Patel RA, True LD, Welti J, Jimenez-Vacas JM, Rodrigues DN, Riisnaes R, Neeb A, Sprenger CT, Swain A, Wilkinson S, Karzai F, Dahut WL, Balk SP, Corey E, Nelson PS, Haffner MC, Plymate SR, de Bono JS, Sharp A.
    Clin Cancer Res; 2022 Aug 15; 28(16):3509-3525. PubMed ID: 35695870
    [Abstract] [Full Text] [Related]

  • 20. Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer.
    Lee CH, Ku JY, Ha JM, Bae SS, Lee JZ, Kim CS, Ha HK.
    Prostate; 2017 Jan 15; 77(1):60-71. PubMed ID: 27550197
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.